Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer’s disease symptoms in high-risk people, ...

A clinical trial of the drug Trontinemab will aim to delay or prevent the symptoms of Alzheimer's disease, Swiss drugmaker Roche says.

The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects ...

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...

Eli Lilly and Company (NYSE:LLY) is one of the top low volatility healthcare stocks to buy now. On July 10, Morgan Stanley ...

Eli Lilly & Company (NYSE:LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

The trial drug Trontinemab is designed to bypass the blood brain barrier, delivering more treatment directly to the brain.